KRAS and neoplasm: 7/8 (88%) methods found mutually exclusive alterations in KRAS, NRAS or BRAF as a predictive biomarker, from which one, two and four methods proposed this marker in conjunction with tumour sidedness, CMS and across all patients, respectively (Supplementary Table 1).